Study: Combination Chemotherapy and Immunotherapy for Dogs with Splenic Hemangiosarcoma
Location: The Animal Medical Center-New York, New York
Contact: Ann Hohenhaus at or 1-212-329-8612

To qualify, dogs must have a histopathologic diagnosis of splenic hemangiosarcoma.

Dogs will be excluded if they have been treated with prior chemotherapeutics for HSA or suffer from any other

Summary: The Cancer Institute at the Animal Medical Center is currently enrolling canine splenic HSA patients into a
clinical trial. All patients will receive standard of care chemotherapy with doxorubicin. This study is a prospective,
randomized, clinical trial with active control, intended to compare the effects of two drug therapies (doxorubicin paired with
immunotherapy, vs. doxorubicin paired with placebo) on the progression free survival time of canine HSA patients after

Cost: Partially funded (owner cost >$1000).

Study#1: Evaluation of the safety of a recombinant viral vector (AAV8) encoding an anti-VEGF
antibody and its ability to delay tumor progression and prolong survival in dogs with splenic
Location: University of Pennsylvania
ontact: Martha MaloneyHuss at  or 1-215-898-6289.

Eligible dogs have a histopathologic diagnosis of splenic hemangiosarcoma (stage II), weigh between 10 and 40 kg, are
otherwise healthy with a life expectancy of at least 2 months, have had a splenectomy within the past two weeks, and have
not yet begun (but intend to undergo) doxorubicin chemotherapy.

Summary: Hemangiosarcoma is an aggressive cancer that commonly occurs in the spleen, liver, and the right side of the
heart. The current standard of care for splenic hemangiosarcoma is surgical removal of the spleen followed by
chemotherapy. Despite surgery and chemotherapy, the disease usually spreads and most dogs succumb to their disease
within 6-12 months of diagnosis. Vascular endothelial growth factor (VEGF) is a growth factor that may contribute to the
spread and growth of hemangiosarcoma. In this clinical trial, we will evaluate the safety and effectiveness of an antibody
therapy designed to inhibit VEGF and delay or prevent spread of the disease after surgery.

Incentive: Fully funded after initial screening.

Study#2: Further Evaluation of the Benefits of a Traditional Chinese Medicine Supplement for Dogs
with Splenic Hemangiosarcoma
Location: University of Pennsylvania
Phone: Please contact the VCIC at 215-573-0302 or email

» Diagnosis of hemangiosarcoma following splenectomy.
» At least 4 kg.
» Not currently undergoing treatment for cancer.
» No other significant health concerns that are an immediate threat to life.
» Ability to administer oral medication (pills) to your dog.

Summary: In a previous study conducted here at PennVet, the mushroom supplement I’m-Yunity® significantly increased
survival time in dogs with splenic hemangiosarcoma. I’m-Yunity® extract effectively delivers the standardized ingredient
polysaccharopeptide (PSP) which can only be isolated from the Coriolus Versicolor mushroom.  In this new trial, we will be
comparing I’m-Yunity’s® effect on survival time and quality of life to the standard chemotherapy treatment.

Owners will be given the opportunity to choose either chemotherapy or I’m-Yunity® as treatment for their dog.  Half of the
dogs getting chemotherapy will be randomly chosen to receive I'm Yunity® concurrently with the chemotherapy, and
owners will not know whether or not their dog is getting I'm Yunity®.  Dogs enrolled in this study will have 11 weekly visits,
followed by monthly follow-up visits until the end of their life.
Comprehensive guide to cancer diagnosis and treatment in cats and dogs
© 2007 Pet Cancer Center. ALL RIGHTS RESERVED.
Last updated 2/18/2017
Please take our short survey to help us understand pet owners' perception of clinical trials.
Clinical trials for spleen hemangiosarcoma in dogs
Open clinical
trials for dogs
Dog Fences Training and Bark Collars Pet Feeders
Find clinical trials for specific tumor types in dogs: